Celltrion’s Monoclonal Antibody Treatment for COVID-19, regdanvimab (CT-P59), Demonstrates Strong Neutralising Activity Against Delta Variant
Business Wire India Pre- clinical data for regdanvimab (CT-P59) demonstrates strong neutralising activity against the Delta variant (B.1.617.2, first identified in India); results show 100% survival rate with virus eradication…